聚多卡醇联合阿替洛尔治疗婴幼儿腮腺区血管瘤的临床研究

［摘要］ 目的 探讨聚多卡醇联合阿替洛尔治疗婴幼儿腮腺区血管瘤的疗效及其对环氧化酶2（cyclooxygenase 2，COX-2）、结缔组织生长因子（connective tissue growth factor，CTGF）、血管内皮生长因子（vascular endothelial growth factor，VEGF）的影响。 方法 选取腮腺区血管瘤患儿76例，随机分为对照组（38例）和观察组（38例），对照组患儿给予阿替洛尔治疗，观察组患儿在此基础上给予瘤内局部注射1%聚多卡醇治疗。比较2组临床疗效及不良反应发生情况，比较治疗前后2组患儿COX-2、CTGF阳性率、VEGF水平及免疫功能。 结果 2组患儿平均服用阿替洛尔6个月，观察组患儿平均注射1%聚多卡醇3个疗程。76例患儿均完成治疗，随访12个月无失访。观察组总有效率显著高于对照组（P＜0.05）。治疗完成后观察组VEGF水平及COX-2、CTGF阳性率显著低于对照组，观察组IgA、IgG及IgM水平均显著高于对照组（P＜0.05）。治疗期间，观察组不良反应发生率显著低于对照组（P＜0.05）。 结论 聚多卡醇联合阿替洛尔治疗婴幼儿腮腺区血管瘤效果良好，且安全性高，具有抑制COX-2、CTGF及VEGF表达的作用。

Effect of polypolycarnitol combined with Atenolol in treatment of infantile hemangioma in parotid region and its effect on COX-2,CTGF

［Abstract］ Objective To study the effect of polypolycarnitol combined with Atenolol in treatment of infantile hemangioma in parotid region and its effect on cyclooxygenase 2(COX-2), connective tissue growth factor(CTGF), vascular endothelial growth factor（VEGF）. Methods Seventy-six patients with hemangioma of parotid gland were randomly divided into control group(38 cases) and observation group(38 cases). In the control group, the children were treated with atenolol, and the observation group was given a local injection of 1% polykarl in the tumor. The clinical efficacy and adverse reactions were compared between two groups.The expression of COX-2, CTGF and VEGF and immune function were compared between two groups of children before and after treatment. Results The two groups took atenolol for an average of 6 months, and the observation group received 1% polycarnitol for 3 courses on average.The treatment was completed in 76 children, followed up for 12 months without loss of follow-up. The total effective rate of observation group was significantly higher than that of control group(P＜0.05). After treatment, the positive rate of COX-2,CTGF and the level of VEGF in observation group were significantly lower than those in control group. The levels of IgA,IgG and IgM in observation group were significantly higher than those in control group(P＜0.05). During the treatment period, compared with the control group, the adverse reactions in observation group were significantly lower(P＜0.05). Conclusion Atenolol combined with polycarnitol is effective and safe in the treatment of infantile hemangioma in parotid region. It can inhibit the expression of COX-2, CTGF and VEGF.